- Home
- » Tags
- » Vemurafenib
Top View
- ATP-Competitive Inhibitors Block Protein Kinase Recruitment to the Hsp90-Cdc37 System
- Pharmacogenetic Testing Last Revision/Review Date: May 19, 2021 P&P # C.6.16
- Genomic Features of Exceptional Response in Vemurafenib
- Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma
- Identification of Pathways Modulating Vemurafenib Resistance in Melanoma Cells Via a 2 Genome-Wide CRISPR/Cas9 Screen
- Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma
- Therapeutic Inhibitors Against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
- Zelboraf® (Vemurafenib)
- BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma LISA WALTER and LUCIE HEINZERLING
- Focus on the Dabrafenib, Vemurafenib, and Trametinib in the Clinical Outcome of Melanoma: a Systematic Review and Meta-Analysis
- 193 Sorafenib Induces Synergistic Effect on Inhibition of Vemurafenib Resistant Melanoma Growth Ankita Srivastava1, Anbalagan Mo
- Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK
- Analysis of Treatment with Vemurafenib and Dabrafenib in Patients With
- Sorafenib Sensitizes Melanoma Cells to Vemurafenib Through Ferroptosis
- Vemurafenib Monograph
- Preclinical Evaluation of Vemurafenib As Therapy for BRAF Mutated
- Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination with MEK Inhibitors for Metastatic Melanoma
- Overview of Current Type I/II Kinase Inhibitors
- Predicting the Effect of Food on Drug Exposure Through an Understanding
- The London School of Economics and Political Science Cancer Medicines
- Targeted Therapies in Melanoma
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Novel Targeted Drugs Approved by the NMPA and FDA in 2019
- Cotellic, INN-Cobimetinib
- February 2021
- Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma
- Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib And
- Combining Tkis in Melanoma
- Early Decline in Serum Phospho-CSE1L Levels in Vemurafenib/Sunitinib-Treated Melanoma and Sorafenib/Lapatinib-Treated Colorectal
- Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma Via the TSP-1/Tgfβ1 Axis
- Vemurafenib) Tablet for Oral Use Electrolyte Abnormalities and Control for Cardiac Risk Factors for QT Initial U.S
- Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Therapeutic Resistance and Susceptibility Is Shaped by Cooperative Multi-Compartment Tumor Adaptation
- ATC/DDD Classification (Temporary)
- Resistance to Molecularly Targeted Therapies in Melanoma
- Cobimetinib + Vemurafenib in Patients with Colorectal Cancer with BRAF
- Study the Efficacy of Sorafenib, Vemurafenib and Dabrafenib on BRAF Wild and Mutated Genes Using Computational Approach. Adv
- Tyrosine Kinase Inhibitor Therapy and Metabolic Remodelling in Papillary Thyroid Cancer
- Efficacy of Vemurafenib in a Trametinib-Resistant Stage IV Melanoma Patient−−Letter
- Phase Iii, Randomized, Double Blind, Placebo-Controlled
- Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Full Prescribing Information for Serous Retinopathy and Retinal Vein Occlusion: Perform an COTELLIC
- Pancreatitis Associated with Newer Classes of Antineoplastic Therapies
- Vemurafenib: the First Drug Approved for BRAF-Mutant Cancer
- Zelboraf (Vemurafenib)
- Reference ID
- Availability of Evidence of Benefits on Overall Survival and Quality of Life Of
- Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
- FDA Approval Summary: Vemurafenib for Treatment of Unresectable Or
- BC Cancer Protocol Summary for the Treatment of BRAF V600 Mutation-Positive Unresectable Or Metastatic Melanoma Using Vemurafenib and Cobimetinib
- COTELLIC (Cobimetinib) Tablets, for Oral Use Serous Retinopathy and Retinal Vein Occlusion: Perform an Initial U.S
- Vemurafenib and Trametinib Reduce Expression of CTGF and IL-8 In
- Preclinical Efficacy of a RAF Inhibitor That Evades Paradoxical MAPK Pathway Activation in Protein Kinase BRAF-Mutant Lung Cancer
- Liste Der Oralen Antineoplastischen Wirkstoffe Stand: 29.06.2021
- Evaluation of Drug Therapy Costs for Patients with Breast Cancer, Melanoma and Renal Cell Carcinoma in Moscow in 2016-2017
- Genotype-Selective Combination Therapies for Melanoma Identified by High Throughput Drug Screening